HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

SELECT trial: semaglutide cut major cardiovascular events 20% in obese non-diabetic adults

Gokhan Can · Dec 24, 2023 · ♥ 4 reactions · 6 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Heart attack, stroke & proceduresWeight, visceral & liver fat
AI summary & key facts

Summarizes the SELECT trial of 2.4 mg weekly semaglutide in about 17,000 adults with obesity but without diabetes, followed for 40 months. The primary composite of CV death, nonfatal MI and nonfatal stroke fell from 8.0% to 6.5%, with benefits for nonfatal MI, all-cause death, blood pressure and weight.

SELECT Trial (Semaglutide)

(This is the most exciting news since statins for the obese?)

~17,000 obese. Half of them on 2.4 mg Semaglutide weekly. Not diabetic. 40 months follow-up.

The primary outcome:

Composite of CV death, nonfatal MI, and nonfatal stroke, for semaglutide vs. placebo, was: 6.5% vs. 8.0% (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.72-0.90, p < 0.001).

Secondary outcomes for semaglutide vs. placebo:

Additional outcomes for semaglutide vs. placebo:

American College of CardiologySemaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity - American College of CardiologyAmit Saha, MDacc.org

Research cited

#semaglutide#bloodpressure#cardiovascular#statins#stroke
← newer: PCSK9 inhibitors on top of statins regressed plaque in GLAGOolder: Medscape news: FDA approves low-dose colchicine for broad ca →